

## References

1. S. Ogg *et al.*, *Nature* **389**, 995, (1997).
2. T. Unterman, R. Costa, R. Lacson, *Clin. Res.* **42**, 213A (1994).
3. T. G. Unterman *et al.*, *Biochem. Biophys. Res. Commun.* **203**, 1835 (1994).
4. T. Unterman, D. Oehler, H. Nguyen, P. Sengupta, R. Lacson, *Prog. Growth Factor Res.* **6**, 119 (1995); R. M. O'Brien *et al.*, *Mol. Cell Biol.* **15**, 1747 (1995); S. V. Allander *et al.*, *Endocrinology* **138**, 4291 (1997).
5. L. A. Nolten, P. H. Steenbergh, J. S. Sussenbach, *J. Biol. Chem.* **271**, 31846 (1996); C. I. Pao *et al.*, *Mol. Endocrinol.* **7**, 1561 (1993).

**Response:** We appreciate the comment by Unterman about our recent report and apologize for not having cited papers by his group (1). We note that the model we cited (2) also considered the possibility that glucocorticoid-stimulated potential, rather than binding of HNF-3, may be influenced by insulin signaling. In our discussion about the possible mechanisms for the antagonism between the insulin/IGF signaling and HNF-3/forkhead proteins, we did not mean to imply that the effects were "direct" or "simple."

**Kui Lin**

**Cynthia Kenyon**

Department of Biochemistry and Biophysics,  
University of California,  
San Francisco, CA 94143-0554, USA  
E-mail: [cynthia\\_kenyon@biochem.ucsf.edu](mailto:cynthia_kenyon@biochem.ucsf.edu)

## References

1. T. Unterman, R. Costa, R. Lacson, *Clin. Res.* **42**, 213A (1994); T. G. Unterman *et al.*, *Biochem. Biophys. Res. Commun.* **203**, 1835 (1994).
2. R. M. O'Brien *et al.*, *Mol. Cell Biol.* **15**, 1747 (1995); R. M. O'Brien and D.K. Granner, in *Diabetes Mellitus*, D. LeRoith, S.I. Taylor, J.M. Olefsky, Eds. (Lippincott-Raven, Philadelphia, PA, 1996), pp.121-131.

## Ending Polio Immunization

In back-to-back Policy Forums on 8 August, A. W. Dove and V. R. Racaniello (p. 779) and H. F. Hull and R. B. Aylward (p. 780) discuss various strategies for the "eventual cessation" of immunization of children against polio, now that the worldwide eradication of the disease is within sight. We, however, would like to add a cautionary point.

If, say, after 5 years of inactivated polio vaccine (IPV) immunization and five further years of nonimmunization, no virus can be detected (even in the susceptible cohorts of nonvaccinated newborns), then intensive surveillance might gradually be ended. It is only at this stage (not likely before the year 2010) that the world could be declared free of poliovirus.

To help this approach, priorities on the

research agenda should be (i) to gain insight in enterovirus RNA sequences that determine transmissibility, as well as the possibility that such sequences are obtained by polioviruses, in particular oral polio vaccine (OPV) Sabin strains, through genetic drift or recombination; (ii) to develop serological tests that are able to detect infected persons in populations vaccinated with inactivated polio vaccine; and (iii) to optimize surveillance strategies, sampling theory, and formulation of criteria for certifying countries as poliovirus-free.

We cannot get absolute proof of the absence of "the needle in the haystack" (poliovirus in the world) before we should want to ban immunization. Thus, immediately after ending immunization, a population of susceptible children will develop who necessarily, but much to our unease, will prove the correctness of the assumptions made. Sad disappointments may therefore follow the ban on polio immunization, and we should be prepared to respond rapidly to unpredicted outbreaks with at-the-ready high-quality diagnostics and, above all, large quantities of vaccine (both OPV and IPV).

**Tjeerd G. Kimman**

**Marion P. G. Koopmans**

**Harrie G. A. M. van der Avoort**

Research Laboratory for Infectious Diseases,  
National Institute of Public Health

## MAMMALIAN GENOTYPING SERVICE

Sponsored by the  
National Heart, Lung, and Blood Institute  
National Institutes of Health

The Mammalian Genotyping Service is funded by the National Institutes of Health to assist in linkage mapping of genes which cause or influence disease. Genotyping is carried out using short tandem repeat polymorphisms at Marshfield, Wisconsin under the direction of Dr. James Weber. Capacity of the Service is currently about 3,000,000 genotypes (DNA samples times polymorphic markers) per year and growing. Although the Service was initially established for genetic projects dealing with heart, lung, and blood diseases, the Mammalian Genotyping Service will now consider all meritorious applications.

To ensure that the most promising projects are undertaken, investigators must submit brief applications that are evaluated by a scientific advisory panel. At this time, only projects involving humans, mice or rats and only projects with  $\geq 10,000$  genotypes will be considered. There are no genotyping fees for approved projects. Application deadlines are every six months.

### Upcoming Application Deadlines

March 31, 1998  
September 30, 1998

For Application Instructions and additional information see:


<http://www.marshmed.org/genetics>


or contact:

Beth Busscher, Center for Medical Genetics  
Marshfield Medical Research Foundation  
1000 N. Oak Avenue  
Marshfield, WI 54449

PHONE: (715) 389-3525 FAX: (715) 389-5757

EMAIL: [busscheb@mflclin.edu](mailto:busscheb@mflclin.edu)



 Academic Press

# Start Your Day with inScight

Science and Academic Press invite you to start your day with **inScight**, the online information service devoted specifically to late-breaking science news. Located at [www.apnet.com/inscight](http://www.apnet.com/inscight), the site is a free service featuring daily topical news items of interest to researchers, practitioners, students, and anyone with an interest in current science issues. The experienced and preeminent news team of the weekly **Science** compiles and provides **inScight** with the day's primary science news stories which are then formatted and maintained online through the Academic Press electronic production services department.

**inScight—**  
**[www.apnet.com/inscight](http://www.apnet.com/inscight)**

Science—  
[www.sciencemag.org](http://www.sciencemag.org)

Academic Press—  
[www.apnet.com/](http://www.apnet.com/) or  
[www.europe.apnet.com/](http://www.europe.apnet.com/)

LK/KJ/FF 18116

and the Environment,  
3720 BA Bilthoven, Netherlands  
E-mail: tg.kimman@rivm.nl

*Response:* Kimman *et al.* have provided a useful addition to the debate over polio eradication by outlining specific recommendations for policy changes. We agree that the cessation of vaccination should only occur after an intermediate stage of IPV use, but it is not clear that this strategy alone will make the transition safe, even with improved monitoring.

We agree that large stocks of polio vaccine should be kept on hand if vaccination is stopped, but feel that IPV would be the only viable choice. The use of OPV to control outbreaks in a population that has never been exposed to wild or vaccine polio carries the danger that live vaccine virus may spread outside of the area targeted for control and cause poliomyelitis. Also, the production of vaccine stocks after the end of vaccination presents a serious biohazard, and Kimman *et al.* do not present a plan to ensure the safety of this process. Retooling vaccine production facilities to operate at biosafety level 4 would represent a substantial added cost for the eradication effort.

Kimman *et al.* do not mention the considerable challenge of accounting for world-

wide laboratory stocks of neurovirulent, transmissible strains of polio—a challenge made more threatening by the possibility that nations or groups could easily obtain and conceal such stocks for future use as biological weapons if vaccination is stopped.

Alan W. Dove

Vincent R. Racaniello  
Department of Microbiology,  
Columbia University College of  
Physicians and Surgeons,  
New York, NY 10032, USA

*Response:* The World Health Organization (WHO) welcomes comments during the development of policy on the final phases of polio eradication. The theoretical risk of ongoing circulation of virulent vaccine-derived polioviruses must be balanced against the existing empirical evidence which indicates that vaccine strains do not circulate indefinitely. Recognized gaps in scientific knowledge on this issue are currently being addressed through a number of ongoing studies. Additional studies have been funded and will begin shortly. In March 1998, WHO will hold the next in a series of meetings on the issues raised by Kimman and Dove and their co-authors. This meeting will review the substantial body of existing data and define the additional evidence needed to


make a scientific recommendation on stopping polio immunization. Laboratory containment of wild poliovirus stocks/infectious materials and potentially infectious materials was discussed in September 1997. A draft plan of action is being developed for review by the scientific community prior to implementation.

Harry F. Hull  
R. Bruce Aylward


Expanded Programme on Immunization,  
World Health Organization,  
1211 Geneva 27, Switzerland

#### Letters to the Editor

Letters may be submitted by e-mail (at science\_letters@aaas.org), fax (202-789-4669), or regular mail (*Science*, 1200 New York Avenue, NW, Washington, DC 20005, USA). Letters are not routinely acknowledged. Full addresses, signatures, and daytime phone numbers should be included. Letters should be brief (300 words or less) and may be edited for reasons of clarity or space. They may appear in print and/or on the World Wide Web. Letter writers are not consulted before publication.



**PROBING the  
improbable**



*Direct fluorescence in situ hybridization with a PNA 18-mer probe (Flu-(C<sub>3</sub>TA<sub>2</sub>)<sub>3</sub>) for the telomere repeats on metaphase chromosomes from cultured human fetal cells. Chromosomes were counterstained with propidium iodide.*

Courtesy of Dr. P. Lansdorp, Terry Fox Laboratory, B.C. Cancer Agency. Reproduced with permission of Oxford University Press from Human Molecular Genetics 5, 685-691 (1996).

Break the bounds of DNA. Peptide Nucleic Acid (PNA) probes empower your research with superior detection and binding capabilities. Exclusively from PerSeptive Biosystems.


**Higher** affinity. A neutral peptide-like backbone ensures **faster** hybridization. Enhanced **specificity**. PNA probes allow for single base pair discrimination. Remarkable **clarity**. See what you have never seen before.

See PNA. Call PerSeptive Biosystems for a FREE applications overview on PNA probes.

Circle No. 19 on Readers' Service Card

US 1.800.899.5858 / Germany +49 6122 9830 0  
France +33 134 5230 30 / UK +44 1992 5071 00  
Japan +81 3 5570-9050  
<http://www.pbio.com>

**FAST FORWARD™**



**PerSeptive Biosystems**

FAST FORWARD is a trademark of PerSeptive Biosystems, Inc.  
©1997 PerSeptive Biosystems, Inc. All rights reserved.